Sonen Capital LLC Reduces Holdings in Edwards Lifesciences Co. (NYSE:EW)

Sonen Capital LLC reduced its position in Edwards Lifesciences Co. (NYSE:EW) by 58.7% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 3,417 shares of the medical research company’s stock after selling 4,865 shares during the period. Sonen Capital LLC’s holdings in Edwards Lifesciences were worth $261,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the company. Martin Capital Advisors LLP grew its position in Edwards Lifesciences by 0.5% during the 4th quarter. Martin Capital Advisors LLP now owns 25,490 shares of the medical research company’s stock worth $1,944,000 after purchasing an additional 128 shares during the last quarter. Legacy Wealth Asset Management LLC raised its stake in Edwards Lifesciences by 0.8% during the 4th quarter. Legacy Wealth Asset Management LLC now owns 16,958 shares of the medical research company’s stock valued at $1,293,000 after acquiring an additional 134 shares during the last quarter. DMC Group LLC lifted its position in Edwards Lifesciences by 4.5% during the 4th quarter. DMC Group LLC now owns 3,561 shares of the medical research company’s stock worth $272,000 after acquiring an additional 154 shares during the period. Granite Harbor Advisors Inc. grew its stake in shares of Edwards Lifesciences by 4.2% in the 3rd quarter. Granite Harbor Advisors Inc. now owns 3,832 shares of the medical research company’s stock valued at $265,000 after purchasing an additional 155 shares during the last quarter. Finally, Stableford Capital II LLC raised its stake in shares of Edwards Lifesciences by 2.7% during the fourth quarter. Stableford Capital II LLC now owns 5,980 shares of the medical research company’s stock worth $449,000 after purchasing an additional 155 shares during the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Edwards Lifesciences

In related news, VP Jean-Luc M. Lemercier sold 14,400 shares of the stock in a transaction on Monday, April 8th. The stock was sold at an average price of $92.32, for a total transaction of $1,329,408.00. Following the sale, the vice president now owns 173,849 shares of the company’s stock, valued at $16,049,739.68. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, VP Jean-Luc M. Lemercier sold 14,400 shares of the company’s stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $92.32, for a total transaction of $1,329,408.00. Following the transaction, the vice president now owns 173,849 shares of the company’s stock, valued at $16,049,739.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Michael A. Mussallem sold 29,350 shares of the firm’s stock in a transaction that occurred on Thursday, April 4th. The stock was sold at an average price of $92.42, for a total transaction of $2,712,527.00. Following the sale, the director now owns 4,486 shares in the company, valued at approximately $414,596.12. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 194,004 shares of company stock valued at $17,166,254. 1.29% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on EW shares. Citigroup lifted their price objective on shares of Edwards Lifesciences from $90.00 to $98.00 and gave the company a “neutral” rating in a research report on Wednesday, April 3rd. Evercore ISI dropped their price target on shares of Edwards Lifesciences from $92.00 to $89.00 and set an “in-line” rating on the stock in a research note on Friday. OTR Global raised shares of Edwards Lifesciences from a “mixed” rating to a “positive” rating in a report on Tuesday, March 26th. Bank of America raised Edwards Lifesciences from a “neutral” rating to a “buy” rating in a report on Thursday, March 7th. Finally, Royal Bank of Canada increased their target price on Edwards Lifesciences from $95.00 to $101.00 and gave the stock an “outperform” rating in a research note on Monday, April 15th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and ten have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $93.33.

Edwards Lifesciences Trading Down 1.8 %

NYSE:EW opened at $86.43 on Friday. Edwards Lifesciences Co. has a 52-week low of $60.57 and a 52-week high of $96.12. The company has a quick ratio of 2.40, a current ratio of 3.38 and a debt-to-equity ratio of 0.09. The stock has a fifty day simple moving average of $90.28 and a 200-day simple moving average of $78.89. The company has a market capitalization of $52.02 billion, a PE ratio of 37.25, a price-to-earnings-growth ratio of 4.29 and a beta of 1.05.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.02. The company had revenue of $1.60 billion during the quarter, compared to analysts’ expectations of $1.58 billion. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 23.34%. On average, equities research analysts expect that Edwards Lifesciences Co. will post 2.76 earnings per share for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.